Book Reviews / Joaquin FUENTES in Autism, 2-4 (December 1998)  

Public ISBD [article]  inAutism > 2-4 (December 1998) . - p.438 Titre : Book Reviews Type de document : Texte imprimé et/ou numérique Auteurs : Joaquin FUENTES, Auteur Article en page(s) : p.438 Langues : Anglais (eng) Index. décimale : PER Périodiques En ligne : http://dx.doi.org/10.1177/1362361398024013 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=207 [article] Book Reviews [Texte imprimé et/ou numérique] / Joaquin FUENTES, Auteur . - p.438. Langues : Anglais (eng) in Autism > 2-4 (December 1998) . - p.438 Index. décimale : PER Périodiques En ligne : http://dx.doi.org/10.1177/1362361398024013 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=207

Brief Report: Antibodies Reacting to Brain Tissue in Basque Spanish Children with Autism Spectrum Disorder and Their Mothers / Christy C. ROSSI in Journal of Autism and Developmental Disorders, 44-2 (February 2014)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 44-2 (February 2014) . - p.459-465 Titre : Brief Report: Antibodies Reacting to Brain Tissue in Basque Spanish Children with Autism Spectrum Disorder and Their Mothers Type de document : Texte imprimé et/ou numérique Auteurs : Christy C. ROSSI, Auteur ; Joaquin FUENTES, Auteur ; Judy WATER, Auteur ; David G. AMARAL, Auteur Article en page(s) : p.459-465 Langues : Anglais (eng) Mots-clés : Autism spectrum disorders  Autoantibody  Brain  International Index. décimale : PER Périodiques Résumé : Previous investigations found that a subset of children with autism spectrum disorder (ASD) in California possessed plasma autoantibodies that reacted intensely with brain interneurons or other neural profiles. Moreover, for several cohorts of American women, maternal autoantibody reactivity to specific fetal brain proteins was highly specific to mothers of children with ASD. We sought to determine whether children and their mothers from a regionally specific cohort from the Basque Country of Spain demonstrated similar reactivity. Some children’s plasma reacted to interneurons, beaded axons or other neural profiles with no difference in the occurrence of these antibodies in children with or without ASD. Findings on the maternal antibodies confirmed previous research; plasma reactivity to fetal brain a combination of proteins at 37 and 73 kDa or 39 and 73 kDa was found exclusively in mothers of children with ASD. En ligne : http://dx.doi.org/10.1007/s10803-013-1859-y Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=223 [article] Brief Report: Antibodies Reacting to Brain Tissue in Basque Spanish Children with Autism Spectrum Disorder and Their Mothers [Texte imprimé et/ou numérique] / Christy C. ROSSI, Auteur ; Joaquin FUENTES, Auteur ; Judy WATER, Auteur ; David G. AMARAL, Auteur . - p.459-465. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 44-2 (February 2014) . - p.459-465 Mots-clés : Autism spectrum disorders  Autoantibody  Brain  International Index. décimale : PER Périodiques Résumé : Previous investigations found that a subset of children with autism spectrum disorder (ASD) in California possessed plasma autoantibodies that reacted intensely with brain interneurons or other neural profiles. Moreover, for several cohorts of American women, maternal autoantibody reactivity to specific fetal brain proteins was highly specific to mothers of children with ASD. We sought to determine whether children and their mothers from a regionally specific cohort from the Basque Country of Spain demonstrated similar reactivity. Some children’s plasma reacted to interneurons, beaded axons or other neural profiles with no difference in the occurrence of these antibodies in children with or without ASD. Findings on the maternal antibodies confirmed previous research; plasma reactivity to fetal brain a combination of proteins at 37 and 73 kDa or 39 and 73 kDa was found exclusively in mothers of children with ASD. En ligne : http://dx.doi.org/10.1007/s10803-013-1859-y Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=223

Bumetanide oral solution for the treatment of children and adolescents with autism spectrum disorder: Results from two randomized phase III studies / Joaquin FUENTES in Autism Research, 16-10 (October 2023)  

Public ISBD [article]  inAutism Research > 16-10 (October 2023) . - p.2021-2034 Titre : Bumetanide oral solution for the treatment of children and adolescents with autism spectrum disorder: Results from two randomized phase III studies Type de document : Texte imprimé et/ou numérique Auteurs : Joaquin FUENTES, Auteur ; Mara PARELLADA, Auteur ; Christina GEORGOULA, Auteur ; Guiomar OLIVEIRA, Auteur ; Stéphane MARRET, Auteur ; Véronique CRUTEL, Auteur ; Cristina ALBARRAN, Auteur ; Estelle LAMBERT, Auteur ; Pierre-François PÉNÉLAUD, Auteur ; Denis RAVEL, Auteur ; Yehezkel BEN ARI, Auteur Article en page(s) : p.2021-2034 Index. décimale : PER Périodiques Résumé : Abstract The efficacy and safety of bumetanide oral solution for the treatment of autism spectrum disorder (ASD) in children and adolescents was evaluated in two international, multi-center, randomized, double-blind, placebo-controlled phase III trials; one enrolled patients aged 7-17?years (SIGN 1 trial) and the other enrolled younger patients aged 2-6?years (SIGN 2). In both studies, patients were randomized to receive bumetanide oral solution twice daily (BID) or placebo BID during a 6-month double-blind treatment period. The primary endpoint was change in Childhood Autism Rating Scale 2 (CARS2) total raw score from baseline to Week 26. Key secondary endpoints included changes in Social Responsiveness Scale-2, Clinical Global Impression Scale, and Vineland Adaptive Behavior Scale. Each study enrolled 211 patients (bumetanide, n?=?107; placebo, n?=?104). Both studies were terminated early due to absence of any significant difference between bumetanide and placebo in the overall studied populations. In both studies, CARS2 total raw score decreased from baseline to Week 26 in the bumetanide and placebo groups, with no statistically significant difference between groups. No differences were observed between treatment groups for any of the secondary efficacy endpoints in either study. In both studies, treatment-emergent adverse events that occurred more frequently with bumetanide than placebo included thirst, polyuria, hypokalemia, and dry mouth. These large phase III trials failed to demonstrate a benefit of bumetanide for the treatment of pediatric ASD compared with placebo. Consequently, the sponsor has discontinued the development of bumetanide for the treatment of this condition. Trial registration: https://clinicaltrials.gov: SIGN 1: NCT03715166; SIGN 2: NCT03715153. En ligne : https://doi.org/10.1002/aur.3005 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=513 [article] Bumetanide oral solution for the treatment of children and adolescents with autism spectrum disorder: Results from two randomized phase III studies [Texte imprimé et/ou numérique] / Joaquin FUENTES, Auteur ; Mara PARELLADA, Auteur ; Christina GEORGOULA, Auteur ; Guiomar OLIVEIRA, Auteur ; Stéphane MARRET, Auteur ; Véronique CRUTEL, Auteur ; Cristina ALBARRAN, Auteur ; Estelle LAMBERT, Auteur ; Pierre-François PÉNÉLAUD, Auteur ; Denis RAVEL, Auteur ; Yehezkel BEN ARI, Auteur . - p.2021-2034. in Autism Research > 16-10 (October 2023) . - p.2021-2034 Index. décimale : PER Périodiques Résumé : Abstract The efficacy and safety of bumetanide oral solution for the treatment of autism spectrum disorder (ASD) in children and adolescents was evaluated in two international, multi-center, randomized, double-blind, placebo-controlled phase III trials; one enrolled patients aged 7-17?years (SIGN 1 trial) and the other enrolled younger patients aged 2-6?years (SIGN 2). In both studies, patients were randomized to receive bumetanide oral solution twice daily (BID) or placebo BID during a 6-month double-blind treatment period. The primary endpoint was change in Childhood Autism Rating Scale 2 (CARS2) total raw score from baseline to Week 26. Key secondary endpoints included changes in Social Responsiveness Scale-2, Clinical Global Impression Scale, and Vineland Adaptive Behavior Scale. Each study enrolled 211 patients (bumetanide, n?=?107; placebo, n?=?104). Both studies were terminated early due to absence of any significant difference between bumetanide and placebo in the overall studied populations. In both studies, CARS2 total raw score decreased from baseline to Week 26 in the bumetanide and placebo groups, with no statistically significant difference between groups. No differences were observed between treatment groups for any of the secondary efficacy endpoints in either study. In both studies, treatment-emergent adverse events that occurred more frequently with bumetanide than placebo included thirst, polyuria, hypokalemia, and dry mouth. These large phase III trials failed to demonstrate a benefit of bumetanide for the treatment of pediatric ASD compared with placebo. Consequently, the sponsor has discontinued the development of bumetanide for the treatment of this condition. Trial registration: https://clinicaltrials.gov: SIGN 1: NCT03715166; SIGN 2: NCT03715153. En ligne : https://doi.org/10.1002/aur.3005 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=513

L'enseignement secondaire des étudiants atteints de syndrome autistique / Joaquin FUENTES

Public ISBD contenu dans Educautisme / Christine PHILIP Titre : L'enseignement secondaire des étudiants atteints de syndrome autistique Type de document : Texte imprimé et/ou numérique Auteurs : Joaquin FUENTES, Auteur ; Carmen NOGRARO, Auteur ; Beatriz ESTEBAN, Auteur ; Jasone AGUIRRE, Auteur Année de publication : 1995 Importance : p.123-128 Langues : Français (fre) Index. décimale : EDU-A EDU-A - Education - Enseignement - Gestion de Classe Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=266 contenu dans Educautisme / Christine PHILIP L'enseignement secondaire des étudiants atteints de syndrome autistique [Texte imprimé et/ou numérique] / Joaquin FUENTES, Auteur ; Carmen NOGRARO, Auteur ; Beatriz ESTEBAN, Auteur ; Jasone AGUIRRE, Auteur . - 1995 . - p.123-128. Langues : Français (fre) Index. décimale : EDU-A EDU-A - Education - Enseignement - Gestion de Classe Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=266

Exemplaires

Code-barres	Cote	Support	Localisation	Section	Disponibilité
aucun exemplaire

Estimating the Burden of Disease for Autism Spectrum Disorders in Spain in 2003 / Elena SANCHEZ-VALLE in Journal of Autism and Developmental Disorders, 38-2 (February 2008)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 38-2 (February 2008) . - p.288-296 Titre : Estimating the Burden of Disease for Autism Spectrum Disorders in Spain in 2003 Type de document : Texte imprimé et/ou numérique Auteurs : Elena SANCHEZ-VALLE, Auteur ; Joaquin FUENTES, Auteur ; Manuel POSADA, Auteur ; Ana VILLAVERDE-HUESO, Auteur ; Eva TOURINO, Auteur ; María José FERRARI-ARROYO, Auteur ; Leticia BOADA, Auteur ; María Concepción MARTIN-ARRIBAS, Auteur ; Ricardo CANAL, Auteur Année de publication : 2008 Article en page(s) : p.288-296 Langues : Anglais (eng) Mots-clés : Pervasive-developmental-disorders Autistic-spectrum-disorders - Burden of disease Disability-adjusted-life-years DALY Epidemiology Index. décimale : PER Périodiques Résumé : Autism Spectrum Disorders (ASD) are lifelong neurodevelopmental disabilities. Burden of Disease is an indicator that provides important information on health status and outcomes such as premature mortality and disability. In order to estimate the burden of disease of ASD in the Spanish population during 2003, we followed the procedures used in the WHO Global Burden of Disease Study. ASD generated 43,928 Disability Adjusted Life Years (DALY) in Spain in 2003, from which 33,797 were attributable to Autistic Disorder and 10,131 were caused by Asperger’s Disorder and Pervasive Developmental Disorder-Not Otherwise Specified. DALY could be a useful tool for health policy makers for setting health service priorities, allocating available resources effectively and providing a comparable measure of output for early intervention. En ligne : http://dx.doi.org/10.1007/s10803-007-0393-1 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=318 [article] Estimating the Burden of Disease for Autism Spectrum Disorders in Spain in 2003 [Texte imprimé et/ou numérique] / Elena SANCHEZ-VALLE, Auteur ; Joaquin FUENTES, Auteur ; Manuel POSADA, Auteur ; Ana VILLAVERDE-HUESO, Auteur ; Eva TOURINO, Auteur ; María José FERRARI-ARROYO, Auteur ; Leticia BOADA, Auteur ; María Concepción MARTIN-ARRIBAS, Auteur ; Ricardo CANAL, Auteur . - 2008 . - p.288-296. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 38-2 (February 2008) . - p.288-296 Mots-clés : Pervasive-developmental-disorders Autistic-spectrum-disorders - Burden of disease Disability-adjusted-life-years DALY Epidemiology Index. décimale : PER Périodiques Résumé : Autism Spectrum Disorders (ASD) are lifelong neurodevelopmental disabilities. Burden of Disease is an indicator that provides important information on health status and outcomes such as premature mortality and disability. In order to estimate the burden of disease of ASD in the Spanish population during 2003, we followed the procedures used in the WHO Global Burden of Disease Study. ASD generated 43,928 Disability Adjusted Life Years (DALY) in Spain in 2003, from which 33,797 were attributable to Autistic Disorder and 10,131 were caused by Asperger’s Disorder and Pervasive Developmental Disorder-Not Otherwise Specified. DALY could be a useful tool for health policy makers for setting health service priorities, allocating available resources effectively and providing a comparable measure of output for early intervention. En ligne : http://dx.doi.org/10.1007/s10803-007-0393-1 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=318

Un modèle de formation pour les personnels ayant en charge des adolescents et des adultes / Joaquin FUENTES

Permalink

Les personnes atteintes d'autisme / Catherine BARTHELEMY  

Permalink

Practice Tools for Screening and Monitoring Insomnia in Children and Adolescents with Autism Spectrum Disorder / Tobias BANASCHEWSKI in Journal of Autism and Developmental Disorders, 52-8 (August 2022)  

Permalink

La qualité de la vie des personnes autistes / Joaquin FUENTES in Bulletin Scientifique de l'arapi (Le), 6 (décembre 2000)

Permalink

Troubles du Spectre Autistique : 10 conseils pour me soutenir / Joaquin FUENTES in Link Autisme-Europe, 63 (Juin 2015)

Permalink

Use of early intervention for young children with autism spectrum disorder across Europe / Erica SALOMONE in Autism, 20-2 (February 2016)  

Permalink

Youth mental health in a populous city of the developing world: results from the Mexican Adolescent Mental Health Survey / Corina BENJET in Journal of Child Psychology and Psychiatry, 50-4 (April 2009)  

Permalink

---

1 (1 - 12 / 12)